Latest news with #Agreement
Yahoo
a day ago
- Business
- Yahoo
Custom Health Enters into Definitive Agreement to Complete Business Combination with Queue Ventures
Vancouver, British Columbia--(Newsfile Corp. - May 30, 2025) - Custom Health, Inc. ("Custom Health"), a technology-enabled healthcare solutions company providing innovative products and services designed to improve the well-being of individuals across North America, has entered into a definitive arrangement agreement dated May 30, 2025 (the "Arrangement Agreement") with Queue Ventures Ltd. ("Queue"). The transaction is expected to provide Custom Health with access to growth capital to support the expansion of its existing business model and operations. In connection with the Transaction, Custom Health and Queue have also entered into an engagement letter with Stifel Nicolaus Canada Inc. ("Stifel") with respect to (the "Offering") (i) a commercially reasonable best efforts private placement of up to 3,000,000 subscription receipts of Custom FundCo (as defined below) ("FundCo Subscription Receipts") at a price per FundCo Subscription Receipt of US$10.00 for aggregate gross proceeds of up to US$30 million, and (ii) a debt financing of up to US$30 million or such other amount and on such terms as may be agreed between Stifel, Queue and Custom Health (the "Debt Financing"). "This milestone is a testament to the power of our model, the trust of our partners, and the dedication of our team," said Shane Bishop, CEO of Custom Health. "We're proud to announce a definitive agreement to take Custom Health public on the TSX - a transformative step that reflects our mission to personalize care at scale. As a public company, we're excited to expand access to our innovative care solutions, improve outcomes for more patients, and deliver value to all our stakeholders." The Transaction Under the Arrangement Agreement with (i) Custom Health, a corporation existing under the laws of Delaware, and Queue, (ii) Custom Merger Sub, Inc. ("Merger Sub"), a corporation existing under the laws of Delaware and a wholly-owned subsidiary of Queue that has been formed for the sole purpose of participating in and facilitating the Arrangement (as defined below), (iii) Queue BC Subco Inc. ("Queue Subco"), a corporation existing under the laws of British Columbia and a wholly-owned subsidiary of Queue that has been formed for the sole purpose of participating in and facilitating the Arrangement, and (iv) Custom Fundco Inc. ("Custom Fundco"), a corporation existing under the laws of British Columbia that has been formed for the sole purpose of participating in and facilitating the Arrangement by conducting the Offering (as defined below), pursuant to which, among other things, Queue proposes to acquire all of the issued and outstanding shares in the capital of Custom Health (the "Custom Shares") by way of a statutory plan of arrangement (the "Arrangement") under the Business Corporations Act (British Columbia) (the "Transaction"). Pursuant to the Arrangement Agreement, and upon the satisfaction or waiver of the conditions set out therein, the following, among other things, will be completed in connection with the consummation of the Transaction: (i) Custom Health will merge with Merger Sub pursuant to the provisions of the Delaware General Corporations Law (the "Merger"); (ii) Custom Fundco will amalgamate with Queue Subco pursuant to the provisions of the Business Corporations Act (British Columbia) (the "Amalgamation"); (iii) the company resulting from the Merger will become a wholly-owned subsidiary of Queue; (iv) the company resulting from the Amalgamation will convey its assets to Queue and be subsequently wound-up; and (v) the securityholders of Custom Health will hold substantially equivalent securities of Queue (following the Transaction, the "Resulting Issuer"). Resulting Issuer Following the completion of the Transaction ("Closing"), the Resulting Issuer will operate as a health technology and solutions company. Closing is subject to a number of conditions, which include, among others, closing of the Offering, receipt of all necessary board, shareholder and regulatory approvals, including the conditional approval of the listing of the common shares of the Resulting Issuer ("Resulting Issuer Shares") on the Toronto Stock Exchange (the "TSX") (the "Listing"). The Listing will be subject to satisfying all of the TSX's initial listing requirements as an Industrial/Technology issuer. Custom Health will also convene a meeting of its shareholders for the purposes of approving the Merger. Immediately prior to Closing, the Resulting Issuer is expected to change its name to "Custom Health Holdings Inc." or such other name as may be agreed to by the parties and accepted by applicable regulators. The Offering Stifel shall act as lead agent and sole bookrunner in connection with the Offering. Stifel has also been granted an option (the "Agents' Option") to increase the size of the Offering by up to 15% which Agents' Option shall be exercisable in whole or in part at any time for up to 48 hours prior to the closing of the Offering (the "Offering Closing Date"). Each FundCo Subscription Receipt will automatically convert into one common share in the capital of Custom FundCo (each, a "FundCo Share") upon satisfaction of certain escrow release conditions (the "Escrow Release Conditions"), subject to adjustment in certain events, at no additional cost to the holder as described in a subscription receipt agreement to be entered into by the parties and a mutually acceptable escrow agent. In connection with Closing, each FundCo Share received by holders of the FundCo Subscription Receipts shall then be converted into one Resulting Issuer Share pursuant to the Amalgamation. In the event that the Escrow Release Conditions are not satisfied prior to the date that is 180 days after the Offering Closing Date or such later date as mutually agreed, the escrow agent will return to holders of FundCo Subscription Receipts an amount equal to the aggregate issue price of the FundCo Subscription Receipts held by them and their pro rata portion of any interest earned thereon. Subject to the receipt of all requisite approvals, the Offering is expected to be completed on or about July 15, 2025 or such other date to be determined between Custom Health, Queue and Stifel. The Resulting Issuer intends to use the net proceeds from the Offering for working capital and general corporate purposes. Following completion of the Transaction, the Resulting Issuer Shares received upon conversion of the FundCo Shares will not be subject to a statutory hold period in Canada. Sponsorship Under the policies of the TSX, the parties to the Transaction will be required to engage a sponsor for the Transaction unless an exemption or waiver from this requirement can be obtained. Disclosure Document In connection with the Transaction, Queue will file a management information circular or other disclosure document under Queue's profile on SEDAR+ at which will contain details regarding the Transaction, the Arrangement, the Offering, the Debt Financing, Queue, Custom Health and the Resulting Issuer (including applicable financial statements). In the event any of the conditions set forth above are not completed or the Transaction does not proceed, Queue will notify shareholders. This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities in any jurisdiction. About Queue Ventures Ltd. Queue was formed under the Business Corporations Act (British Columbia) on October 29, 2021 and is an unlisted reporting issuer in each of British Columbia and Alberta. Queue has no commercial operations and no assets other than cash. About Custom Health Custom Health provides a comprehensive technology-enabled medication management and managed care solution, resulting in 98%1 medication adherence for its patients across the United States and Canada. Custom Health is focused on serving poly-med patients with chronic conditions, representing an estimated market of 78 million2 adults in North America. These patients take multiple medications several times throughout the day and often struggle to adhere to their prescription regimen, presenting a significant challenge and costing the North American healthcare system an estimated US$550 billion per year3. Further Information Queue and Custom Health plan to issue additional press releases providing further details in respect of the Transaction, the Offering, the Debt Financing and other material information as it becomes available. For further information, please contact Custom Health This press release does not constitute an offer of securities for sale in the United States. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and such securities may not be offered or sold within the United States absent U.S. registration or an applicable exemption from U.S. registration requirements. As noted above, completion of the Transaction is subject to a number of conditions. There can be no assurance that the Transaction will be completed as proposed or at all. Investors are cautioned that, except as disclosed in the management information circular or other disclosure document to be prepared in connection with the Transaction, any information released or received with respect to the Transaction may not be accurate or complete and should not be relied upon. No stock exchange or regulatory authority has passed upon the merits of the Transaction or approved or disapproved of the contents of this news release. All information contained in this news release with respect to Queue was supplied by Queue, and Custom Health and its directors and officers have relied on Queue for such information. Cautionary Note Regarding Forward-Looking Information This press release contains statements which constitute "forward-looking information" within the meaning of applicable securities laws, including statements regarding the plans, intentions, beliefs and current expectations of Queue and Custom Health with respect to the Transaction, the Offering, the Debt Financing, the Listing, and the future business activities and operating performance of the Resulting Issuer. Forward-looking information is often identified by the words "may", "would", "could", "should", "will", "intend", "plan", "anticipate", "believe", "estimate", "expect" or similar expressions and includes information regarding: expectations regarding whether the Transaction will be consummated and whether the Offering or Debt Financing will be completed, including whether conditions to the consummation of the Transaction and completion of the Offering and Debt Financing will be satisfied, the timing and terms for completing the Transaction and the Offering and Debt Financing, and expectations for the effects of the Transaction or the ability of the Resulting Issuer to successfully achieve business objectives. Investors are cautioned that forward-looking information is not based on historical facts but instead reflect management of Queue and Custom Health's management, estimates or projections concerning future results or events based on the opinions, assumptions and estimates of management considered reasonable at the date the statements are made. Although Queue and Custom Health believe that the expectations reflected in such forward-looking information are reasonable, such information involves risks and uncertainties, and undue reliance should not be placed on such information, as unknown or unpredictable factors could have material adverse effects on future results, performance or achievements of the combined company. The reader should not place undue reliance on these forward-looking statements, as there can be no assurances that the plans, initiatives or expectations upon which they are based will occur. Among the key factors that could cause actual results to differ materially from those projected in the forward-looking information are the following: the ability to consummate the Transaction and/or the Offering and Debt Financing; the ability of Custom Health to meet its obligations under its material agreements; the ability to obtain requisite regulatory and other approvals and the satisfaction of other conditions to the consummation of the Transaction and/or the Offering and Debt Financing on the proposed terms and schedule; investor demand and interest in the Offering and Debt Financing; the potential impact of the announcement or consummation of the Transaction and/or the Offering and Debt Financing on relationships, including with regulatory bodies, employees, suppliers, customers and competitors; changes in general economic, business and political conditions, including changes in the financial markets; changes in applicable laws; compliance with extensive government regulation; and the diversion of management time on the Transaction and/or the Offering and Debt Financing. This forward-looking information may be affected by risks and uncertainties in the business of Queue and Custom Health and market conditions. Should one or more of these risks or uncertainties materialize, or should assumptions underlying the forward- looking information prove incorrect, actual results may vary materially from those described herein as intended, planned, anticipated, believed, estimated or expected. Although Queue and Custom Health have attempted to identify important risks, uncertainties and factors which could cause actual results to differ materially, there may be others that cause results not to be as anticipated, estimated or intended. Queue and Custom Health do not intend, and do not assume any obligation, to update this forward-looking information except as otherwise required by applicable law. ________________________ 1 BMC Geriatrics, "Medication adherence support of an in-home electronic medication dispensing system for individuals living with chronic conditions: a pilot randomized controlled trial" 2 CDC, "Prevalence of Multiple Chronic Conditions Among US Adults, 2018"; Statistics Canada; BMC, "Chronic disease multimorbidity among the Canadian population: prevalence and associated lifestyle factors"; Statista, "Resident population of Canada in 2022, by gender and age group" 3 Sage Journals, "Cost of Prescription Drug-Related Morbidity and Mortality"; National Library of Medicine, "Cost-related nonadherence to prescription medications in Canada: a scoping review" # # # Not for distribution to United States newswire services or for dissemination in the United States. To view the source version of this press release, please visit Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 days ago
- General
- Yahoo
I-5 bridge replacement program unveils plan to minimize impact on historic sites
PORTLAND, Ore. () — The Interstate Bridge Replacement Program is asking for help in ensuring the project reduces its impact on historic sites in the Portland and Vancouver areas. Section 106 of the National Historic Preservation Act requires agencies to assess whether federally-funded projects could harm cultural resources and, if so, determine how to minimize that harm. As a result, the team behind ongoing efforts to replace the Interstate 5 Bridge is on its Draft Programmatic Agreement. Residents appeal Oaks Amusement Park's plan to install 135-foot Drop Tower ride The proposed agreement reveals how leaders would address the program's potential 'adverse effects' to historic places, such as physical damage, removal from their original location or alterations to the features that make the sites historic. IBRP has identified more than 10 places that could face adverse effects of construction. According to the program's , the Harbor Shops along 11915 N Center Ave. and Jantzen Beach Water Tank at N Center St and N Jantzen Ave. are the two Portland sites that could be completely demolished under the program. In Washington, around one-third of an acre of the Fort Vancouver National Historic Site and nearly one-quarter of an acre of the Vancouver Barracks Historic District would be demolished. Program leaders have selected different 'treatment measures' for the identified areas, but some — like the Northbound lanes of the I-5 bridge — will have their historic materials salvaged for future use. 'Preference will be given first to the public ownership and reuse of these materials within public spaces or structures in or adjacent to the [Area of Potential Effect] and second, to public ownership and reuse of these materials within public spaces or structures outside the APE,' the drafted Programmatic Agreement reads. Portland Fleet Week to bring extended bridge lifts next week The program will also consider offering materials to the general public if public agencies don't express interest in using them. Community members have until June 8 to weigh in on the PA proposal. They can submit their feedback through the online form or by emailing culturalresources@ Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
India Gazette
2 days ago
- Entertainment
- India Gazette
"Honest filmmakers will not have problems...": Ajay Devgn backs 8-hour shifts for mothers amid reports of Deepika Padukone's exit from Spirit
Mumbai (Maharashtra) [India], May 29 (ANI): Actor Ajay Devgn backed the 8-hour shifts for mothers amid reports of Deepika Padukone's exit from Sandeep Reddy Vanga's film 'Spirit.' The film has been in the news lately after reports claimed that Deepika decided to walk away from the project due to certain working demands, including a request for an 'eight-hour workday.' While this sparked debate online, actor Ajay Devgn seems to have spoken in support of Deepika Padukone at the trailer launch of 'Maa', an upcoming horror film that stars Kajol in the lead. When asked about his views on the demands for an 8-hour shift, Devgn, without taking names, said, 'It's not that it's not going down well with people. Most of the honest filmmakers will not have problems with it. Apart from this, being a mother and working for eight hours, most people have started working eight- to nine-hour shifts.' 'It's person to person, and I feel most of the industry understands this,' he added. Earlier, Deepika was expected to star opposite Prabhas in Spirit, a film backed by T-Series and Bhadrakali Pictures. However, she is reportedly no longer part of the project. The film is directed by Animal director Sandeep Reddy Vanga. Following Deepika's reported exit, the makers confirmed that actress Triptii Dimri, who was also seen in Animal, has joined the cast of Spirit. Just a couple of days back, Vanga took to his X and dropped a fiery post. Though he did not name anyone directly, many believe Vanga was referring to Deepika Padukone, who reportedly stepped away from the project recently. In a post shared on his official X, Vanga voiced frustration over a broken 'unsaid NDA' and alleged betrayal of trust, and wrote, 'When I narrate a story to an actor, I place 100 per cent faith. There is an unsaid NDA (Non-Disclosure Agreement) between us. But by doing this, you've 'DISCLOSED' the person that you are...' (ANI)
India.com
2 days ago
- Entertainment
- India.com
Ajay Devgn Backs Deepika Padukone Amid Sandeep Reddy Vanga Feud: Honest Filmmakers Will Have No Problem…
Mumbai: Actor Ajay Devgn backed the 8-hour shifts for mothers amid reports of Deepika Padukone's exit from Sandeep Reddy Vanga's film 'Spirit.' The film has been in the news lately after reports claimed that Deepika decided to walk away from the project due to certain working demands, including a request for an 'eight-hour workday.' While this sparked debate online, actor Ajay Devgn seems to have spoken in support of Deepika Padukone at the trailer launch of 'Maa', an upcoming horror film that stars Kajol in the lead. When asked about his views on the demands for an 8-hour shift, Devgn, without taking names, said, "It's not that it's not going down well with people. Most of the honest filmmakers will not have problems with it. Apart from this, being a mother and working for eight hours, most people have started working eight- to nine-hour shifts." "It's person to person, and I feel most of the industry understands this," he added. Earlier, Deepika was expected to star opposite Prabhas in Spirit, a film backed by T-Series and Bhadrakali Pictures. However, she is reportedly no longer part of the project. The film is directed by Animal director Sandeep Reddy Vanga. Following Deepika's reported exit, the makers confirmed that actress Triptii Dimri, who was also seen in Animal, has joined the cast of Spirit. Just a couple of days back, Vanga took to his X and dropped a fiery post. Though he did not name anyone directly, many believe Vanga was referring to Deepika Padukone, who reportedly stepped away from the project recently. In a post shared on his official X, Vanga voiced frustration over a broken "unsaid NDA" and alleged betrayal of trust, and wrote, "When I narrate a story to an actor, I place 100 per cent faith. There is an unsaid NDA (Non-Disclosure Agreement) between us. But by doing this, you've 'DISCLOSED' the person.
Cision Canada
2 days ago
- Business
- Cision Canada
Webull Announces Redemption of Incentive Warrants
ST. PETERSBURG, Fla., May 29, 2025 /CNW/ -- Webull Corporation (Nasdaq: BULL) ("Webull" or the "Company"), the owner of the Webull online investment platform, announced today that it has delivered a notice of redemption to redeem on June 30, 2025 (the "Redemption Date") all of its outstanding incentive warrants (the "Incentive Warrants"; Nasdaq: BULLZ), which are exercisable for the Company's Class A ordinary shares, par value $0.00001 per share (the "Class A Ordinary Shares") at an exercise price of $10.00 per share and which were issued in connection with the closing of the Company's business combination under the Warrant Agreement, dated as of April 10, 2025 (the "Warrant Agreement"), by and between the Company and Continental Stock Transfer & Trust Company, as warrant agent (the "Warrant Agent"). Any Incentive Warrants that remain unexercised at 5:00 p.m., New York City time, on the Redemption Date will be void and no longer exercisable and their holders will have no rights with respect to those Incentive Warrants, except to receive a redemption price of $0.01 per Incentive Warrant they hold (the "Redemption Price"). At the direction of the Company and pursuant to the Warrant Agreement, the Warrant Agent has delivered a notice of redemption to each registered holder of the outstanding Incentive Warrants. Under the terms of the Warrant Agreement, the Company has the right to redeem all of the outstanding Incentive Warrants if the volume weighted average price of the Class A Ordinary Shares for the 30 trading-day period ending on the third trading day prior to the date on which the notice of redemption is given equals or exceeds $18.00 per Class A Ordinary Share. The volume weighted average price of the Class A Ordinary Shares for the 30 trading-day period ending on May 23, 2025, which is the third trading day prior to the date of the redemption notice, was greater than $18.00 per share. The Incentive Warrants may be exercised by the holders thereof before 5:00 p.m. New York City time on the Redemption Date to purchase fully paid and non-assessable shares of Class A Ordinary Shares underlying such Incentive Warrants, at the exercise price of $10.00 per share. None of the Company, its board of directors or employees has made or is making any representation or recommendation to any holder of the Incentive Warrants as to whether to exercise or refrain from exercising any Incentive Warrants. A prospectus covering the Class A Ordinary Shares issuable upon the exercise of the Incentive Warrants is included in a Registration Statement on Form F-1 (Registration No. 333-286880) (the "Registration Statement"), filed with, and declared effective by, the U.S. Securities and Exchange Commission (the "SEC"). Questions concerning redemption or exercise of the Incentive Warrants can be directed to Continental Stock Transfer & Trust Company, 1 State Street, 30th Floor, New York, New York 10004, Attention: Compliance Department, telephone number (212) 509-4000. No Offer or Solicitation This press release shall not constitute an offer to sell or the solicitation of an offer to buy or of a decision to exercise or to redeem any securities of the Company, nor shall there be any sale of any securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About Webull Webull Corporation (NASDAQ: BULL) owns and operates Webull, a leading digital investment platform built on next-generation global infrastructure. Through its global network of licensed brokerages, Webull offers investment services in 14 markets across North America, Asia Pacific, Europe, and Latin America. Webull serves more than 24 million registered users globally, providing retail investors with 24/7 access to global financial markets. Users can put investment strategies to work by trading global stocks, ETFs, options, futures, and fractional shares through Webull's trading platform, which seamlessly integrates market data and information, its user community, and investor education resources. Learn more at You may also access certain information on Webull and its securities on the website of the SEC at where Webull will, among others, be filing reports, such as Reports on Form 6-K and its Annual Report on Form 20-F. Cautionary Note Regarding Forward-Looking Statements This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained in this press release or other statements of the Company, including statements related to the planned redemption of the Incentive Warrants, the issuance of shares upon exercise of the Incentive Warrants or the planned payment of the Redemption Price, are forward-looking statements. Some of these forward-looking statements can be identified by the use of forward-looking words, including "anticipate," "expect," "suggests," "plan," "believe," "predict," "potential," "seek," "future," "propose," "continue," "intend," "estimates," "targets," "projects," "should," "could," "would," "may," "will," "forecast" or the negatives of these terms or variations of them or similar terminology although not all forward-looking statements contain such terminology. All forward-looking statements are based upon current estimates and forecasts and reflect the reasonable views, assumptions, expectations, and opinions of the Company and its management as of the date of this press release, and are therefore subject to a number of factors, risks and uncertainties, some of which are not currently known to the Company and its management and could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Some of these factors include, but are not limited to: (1) the ability of the Company to capitalize on the anticipated benefits of the business combination, to grow and manage growth profitably, maintain relationships and deepen engagement with users, customers and suppliers, and retain its management and key employees; (2) the reliance of key functions of the Company's business on third-parties and the risk that the Company's platform and systems rely on software and applications that are highly technical and may contain undetected errors that could result in unexpected network interruptions, failures, security breaches, or computer virus attacks; (3) the risks associated with the Company's global operations and continued global expansion, including, but not limited to, the risks related to complex or constantly evolving political or regulatory environments that may result in substantial costs or require adverse changes to the Company's business practices; (4) the Company's estimates of expenses and costs (including costs related to the business combination), of profitability or of other operational and financial metrics as well as the Company's expectations regarding demand for and market acceptance of its products and service; (5) the Company's reliance on trading related income, including payment for order flow ("PFOF"), and the risk of new regulation or bans on PFOF and similar practices; (6) the Company's exposure to fluctuations in interest rates, rapidly changing interest rate environments, volatile prices of securities and trading volumes; (7) the Company's reliance on a limited number of market makers and liquidity providers to generate a large portion of its revenues, and the negative impact of the loss of any of those market makers or liquidity providers; (8) the effects of competition in the Company's industry and the Company's need to constantly innovate and invest in new markets, products, technologies or services to retain, attract and deepen engagement with users; (9) changes in international trade policies and trade disputes that could result in tariffs, taxes or other protectionist measures adversely affecting our business; (10) risks related to general political, economic and business conditions globally and in jurisdictions where the Company operates; (11) risk of further actions taken by various government bodies in the United States that have made the Company the subject of inquiries and investigations relating to concerns about our connections to China; (12) the risk that the failure to protect customer data and privacy or to prevent security breaches relating to the Company's platform could result in economic loss, damage to its reputation, deter customers from using its products and services, and expose it to legal penalties and liability; (13) risks related to the Company's need as a regulated financial services company to develop and maintain effective compliance and risk management infrastructures as well as to maintain capital levels required by regulators and self-regulatory organizations; (14) the ability to meet, or continue to meet, stock exchange listing standards; (15) the possibility of adverse developments in pending or new litigation and regulatory investigations; (16) risks related to the Company's securities and its status as a foreign private issuer and the fact that the information the Company is required to file with or furnish to the SEC may be less extensive and less timely compared to that required to be filed with the SEC by U.S. domestic issuers; (17) the effectiveness of the Registration Statement for resales or exercises of our warrants throughout the 30-day Redemption Period (as defined in the Warrant Agreement) as well as the risks related to the offer and resale of our securities, such as dilution from the issuance of additional Class A Ordinary Shares upon the exercise of warrants, and increased volatility, or significant declines, in the price of our securities based on increased trading activity and the perception that sales of our securities may occur; and (18) other risks and uncertainties that are more fully described in filings made, or to be made, by the Company with the SEC, including in the sections entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Company's filings with the SEC. The foregoing list of factors is not exhaustive. Reported results should not be considered an indication of future performance. There may be additional risks that the Company and its management presently do not know about or that the Company and its management currently believe are immaterial that could also cause actual results to differ materially from those contained in the forward-looking statements. In light of these factors, risks and uncertainties, the forward-looking events and circumstances discussed in this press release may not occur, and any estimates, assumptions, expectations, forecasts, views or opinions set forth in this press release should be regarded as preliminary and for illustrative purposes only and accordingly, undue reliance should not be placed upon the forward-looking statements. The Company assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by law. Webull Media Relations 5W Public Relations Nicholas Koulermos [email protected] (212) 999-5585 SOURCE Webull Corporation
